1.98

1.02% +0.02

Pre-market: 1.9694 -0.0106 -0.54%

Ocugen Inc (OCGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Ocugen Inc stock is currently priced at $1.98, with a 24-hour trading volume of 9.41M. It has seen a +1.02% increased in the last 24 hours and a +24.53% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.88 pivot point. If it approaches the $2.08 resistance level, significant changes may occur.

Previous Close:

$1.96

Open:

$1.91

24h Volume:

9.41M

Market Cap:

$509.51M

Revenue:

Net Income/Loss:

$-63.08M

P/E Ratio:

-5.3514

EPS:

-0.37

Net Cash Flow:

$-72.53M

1W Performance:

+18.56%

1M Performance:

+24.53%

6M Performance:

+447.26%

1Y Performance:

+185.63%

1D Range:

$1.90

$2.06

52W Range:

$0.345

$2.105

Ocugen Inc Stock (OCGN) Company Profile

Name

Ocugen Inc

Sector

Healthcare (1211)

Industry

Biotechnology (697)

Phone

484-328-4701

Address

5 Great Valley Parkway, Suite 160, Malvern, PA

Employee

Twitter

@Ocugen

Next Earnings Date

2024-05-20

Latest SEC Filings

OCGN's Discussions on Twitter

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-01-23	Upgrade	Chardan Capital Markets	Neutral → Buy
Aug-23-22	Initiated	Mizuho	Buy
Jun-15-22	Resumed	ROTH Capital	Buy
Jun-02-22	Initiated	Cantor Fitzgerald	Overweight
Jul-26-21	Initiated	Noble Capital Markets	Outperform
Jun-11-21	Downgrade	ROTH Capital	Buy → Neutral
May-07-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-09-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-04-21	Upgrade	H.C. Wainwright	Neutral → Buy

View All

Ocugen Inc Stock (OCGN) Latest News

Ocugen (NASDAQ:OCGN) Shares Gap Down to $1.96 - MarketBeat

MarketBeat

Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch

MarketWatch

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important ... - GlobeNewswire

GlobeNewswire

Ocugen Advances with Phase 1/2 Trial for Stargardt Disease Treatment - MyChesCo

MyChesCo

Ocugen completes second cohort dosing in Stargardt trial - Investing.com South Africa

Investing.com South Africa

Ocugen Advances Gene Therapy Trials, Targets 2026 for Key Regulatory Approvals - MyChesCo

MyChesCo

Ocugen Inc Stock (OCGN) Financials Data

Ocugen Inc (OCGN) Net Income 2024

OCGN net income (TTM) was -$63.08 million for the quarter ending December 31, 2023, a +27.33% increase year-over-year.

Ocugen Inc (OCGN) Cash Flow 2024

OCGN recorded a free cash flow (TTM) of -$72.53 million for the quarter ending December 31, 2023, a -12.39% decrease year-over-year.

Ocugen Inc (OCGN) Earnings per Share 2024

OCGN earnings per share (TTM) was -$0.27 for the quarter ending December 31, 2023, a +28.95% growth year-over-year.

Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.